Moran Wealth Management LLC Cuts Stake in DaVita Inc. $DVA

Moran Wealth Management LLC reduced its holdings in shares of DaVita Inc. (NYSE:DVA) by 63.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,347 shares of the company’s stock after selling 73,857 shares during the period. Moran Wealth Management LLC owned about 0.06% of DaVita worth $6,175,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in DVA. Farther Finance Advisors LLC increased its stake in DaVita by 199.7% during the 1st quarter. Farther Finance Advisors LLC now owns 1,070 shares of the company’s stock worth $163,000 after buying an additional 713 shares during the period. SG Americas Securities LLC purchased a new stake in DaVita during the 1st quarter worth approximately $846,000. Fifth Third Bancorp increased its stake in DaVita by 5.0% during the 1st quarter. Fifth Third Bancorp now owns 4,274 shares of the company’s stock worth $654,000 after buying an additional 204 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in DaVita by 22.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,351 shares of the company’s stock worth $666,000 after buying an additional 800 shares during the period. Finally, Exchange Traded Concepts LLC increased its stake in DaVita by 8.9% during the 1st quarter. Exchange Traded Concepts LLC now owns 970 shares of the company’s stock worth $148,000 after buying an additional 79 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the sale, the insider owned 26,038 shares of the company’s stock, valued at $3,905,700. The trade was a 8.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

DaVita Price Performance

Shares of NYSE:DVA opened at $126.53 on Wednesday. The stock has a market cap of $9.05 billion, a P/E ratio of 12.44, a P/E/G ratio of 0.89 and a beta of 1.13. The firm has a fifty day moving average price of $132.66 and a 200 day moving average price of $138.88. DaVita Inc. has a 1-year low of $122.93 and a 1-year high of $179.60.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, topping analysts’ consensus estimates of $2.70 by $0.25. The firm had revenue of $3.38 billion during the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. DaVita’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Sell-side analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on DVA. Bank of America lowered their price target on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a report on Wednesday, September 10th. Truist Financial set a $140.00 price target on shares of DaVita in a report on Tuesday. Wall Street Zen cut shares of DaVita from a “buy” rating to a “hold” rating in a report on Saturday. Barclays lowered their price target on shares of DaVita from $160.00 to $149.00 and set an “equal weight” rating for the company in a report on Thursday, October 9th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of DaVita in a report on Wednesday, October 8th. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $153.25.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.